Table 1.
Baseline characteristics of study subjects.
| Characteristics | Overall | Patients with cardiac injury | Patients without cardiac injury | p |
|---|---|---|---|---|
| (n = 27) | (n = 13) | (n = 14) | ||
| Age (years) | 63 [58, 70] | 63 [59, 70] | 63 [57, 70] | 0.697 |
| Male n (%) | 8 (29.6) | 4 (30.8) | 4 (28.6) | 0.999 |
| Illness classification n (%) | 0.054 | |||
| Mild | 16 (59.3) | 5 (38.5) | 11 (78.6) | |
| Severe/critical | 11 (40.7) | 8 (61.5) | 3 (21.4) | |
| Length of hospital stay (days) | 11 [8, 18] | 11 [9, 24] | 10 [8, 13] | 0.205 |
| Presence of comorbidities | ||||
| History of hypertension n (%) | 4 (14.8) | 1 (7.7) | 3 (21.4) | 0.596 |
| History of diabetes mellitus n (%) | 5 (18.5) | 2 (15.4) | 3 (21.4) | 0.999 |
| History of coronary heart disease n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| History of heart failure n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| History of atrial fibrillation n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| History of cardiomyopathy n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Laboratory values on admission | ||||
| WBC (109/L) | 5.7 [4.6, 6.7] | 5.9 [4.5, 8.1] | 5.5 [4.7, 6.6] | 0.607 |
| Hb (1012/L) | 121 [114, 130] | 123 [112, 129] | 120 [115, 130] | 0.797 |
| PLT (109/L) | 203 [169, 253] | 192 [178, 238] | 216 [165, 253] | 0.738 |
| ALT (U/L) | 32 [20, 45] | 32 [24, 42] | 28 [17, 45] | 0.425 |
| AST (U/L) | 27 [19, 35] | 32 [24, 48] | 22 [16, 30] | 0.057 |
| LDH (U/L) | 258 [171, 338] | 332 [227, 422] | 185 [156, 274] | 0.046 |
| Creatinine (umol/L) | 52 [46, 67] | 64 [51, 76] | 51 [44, 59] | 0.027 |
| hs-cTnI (pg/mL) | 6.3 [2.2, 14.6] | 9.9 [5.6, 20.6] | 5.3 [2.0, 6.8] | 0.061 |
| NT-proBNP (pg/mL) | 278 [121, 388] | 390 [324, 530] | 123 [116, 274] | 0.020 |
| hs-CRP (mg/L) | 10.8 [2.6, 74.7] | 29.0 [5.5, 81.4] | 3.6 [2.3, 33.9] | 0.219 |
| IL-6 (pg/mL) | 12.6 [4.8, 20.3] | 9.2 [5.2, 12.9] | 17.4 [8.3, 24.3] | 0.418 |
| D-dimer (ng/mL) | 337 [292, 847] | 332 [313, 912] | 346 [222, 749] | 0.554 |
| Treatments during hospitalization | ||||
| Antibiotics n (%) | 12 (44.4) | 6 (46.2) | 6 (42.9) | 0.870 |
| Corticosteroids n (%) | 5 (18.5) | 3 (23.1) | 2 (14.3) | 0.557 |
| Antiviral drugs n (%) | 19 (70.4) | 10 (76.9) | 9 (64.3) | 0.472 |
| Immunoglobulin n (%) | 1 (3.7) | 0 (0.0) | 1 (7.1) | 0.326 |
| Oxygen inhalation n (%) | 16 (59.3) | 9 (69.2) | 7 (50.0) | 0.310 |
| Mechanical therapy n (%) | 2 (7.4) | 2 (15.4) | 0 (0.0) | 0.127 |
WBC, white blood cell; Hb, hemoglobin; PLT, platelets; ALT, glutamic-pyruvic transaminase; AST, glutamic-oxalacetic transaminease; LDH, lactate dehydrogenase; hs-cTnI, high-sensitivity cardiac troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6.